With COVID-19 vaccine stocks Pfizer and Moderna receiving so much attention, the author of today’s article notes that “This leaves a lot of biotech stocks lacking the attention they deserve. While this is bad news for current holders of these stocks, it is an opportunity for new ones.” With this in mind, he proceeds to highlight three “under-loved” biotech stocks…
Which biotechs are the hottest acquisition targets heading into 2021 – and which large drugmakers are likely to seek to acquire them? Seventy-eight members of the biopharma investment community offered their opinions in a recent Bloomberg Intelligence survey – and today’s article outlines their biotech acquisition predictions. For more, CLICK HERE.
“With multiple potential blockbusters in development, and a track record that proves the company knows how to launch a new drug… [this] stock is probably worth the risk right now,” advises the author of today’s article in regards to the biotech he examines, which, having just launched its first rare disease drug last spring, could receive its fourth new drug…
While the small biotech company featured in today’s article is not working on solving the health problem of the day – COVID-19 – it is solving a major problem that affects one in eight couples and is more prevalent than diabetes, asthma and depression. And with the company having “a clear-cut mission, great management, and a history of revenue growth”,…
Small and midcap stocks – or “smidcaps” – have had a strong November, and the author of today’s article asserts that this strong performance will continue: “This group has been beaten and battered for so long that many people simply doubt the move. But this is a big mistake. I don’t know about the next few days ahead, but smidcaps…
What’s attractive about stocks with a market value around $1 billion? The author of today’s article explains that “At that size, a stock is small enough so that it hasn’t yet been “discovered” by a lot of Wall Street firms, but big enough to have some heft and staying power.” Each year he selects ten stocks hovering around the billion-dollar…
“Once a tried-and-true [COVID-19] vaccine is developed and subsequently incorporated as standard fare in medical practice, one driver of biotech will be mergers and acquisitions,” advises the author of today’s article. He proceeds to highlight an ETF that could benefit from this particular driving force – a fund that has generated a 30% return this year. For more, CLICK HERE.
Thanksgiving means it’s a shortened trading week – and today’s article features two biotech stocks to consider shorting this shortened week based on technical analysis and quantitative ratings. For these two biotech stocks that “look bearish and may present interesting investing opportunities on the short side,” CLICK HERE.
“When it comes to consistent profitability, long-term growth, large competitive moats, and innovation, medical device companies can provide better returns in the long run” compared to biotech stocks, advises the author of today’s article. He proceeds to highlight three medical device stocks which, while not having generated the massive returns some biotech stocks have this year, have handily beaten the…
The three biotech stocks highlighted in today’s article are ones to watch carefully in the coming weeks, advises the author, as important news drops are expected – and in the case of two of the stocks, those news drops are related to the companies’ COVID-19 vaccine candidates. For more on these three biotech stocks to watch throughout the remainder of…